ReviewFrontiers in medicine2026
Pathogenic mechanisms in Fabry disease.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VCAM-1 as a biomarker of early cardiac phenotypic changes in Fabry disease.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anderson-Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-galactosidase A, resulting in progressive accumulation of glycosphingolipids, particularly globotriaosylceramide (Gb3), across multiple organs. FD exhibits marked phenotypic variability influenced by residual enzyme activity, mutation type, and X-chromosome inactivation. Pathogenic mechanisms involve genetic, enzymatic, and metabolic dysregulation, leading to lysosomal dysfunction, inflammation, oxidative stress, mitochondrial impairment, and autophagic defects. Multi-system involvement includes vasculopathy, cardiovascular abnormalities such as left ventricular hypertrophy and arrhythmias, progressive renal injury, central nervous system lesions with cognitive and psychiatric manifestations, and peripheral neuropathy characterized by pain and autonomic dysfunction. Accumulation of Gb3 and its derivative globotriaosylsphingosine (lyso-Gb3) underlies both direct cellular toxicity and secondary pathological processes, including inflammatory activation, oxidative damage, and ion-channel dysregulation. This review synthesizes current understanding of the molecular and cellular pathogenesis of FD, highlights mechanisms underlying phenotypic variability, and integrates organ-specific manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.